Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering

GLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
June 16, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting

End of Phase 2 Meeting has been Rescheduled for July 29th Meeting to Discuss Upcoming Clinical Development Plan and Protocol Designs Strategic Partnership Discussions Expected to Accelerate...
June 11, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

GLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing precision...
May 15, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
May 13, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
May 08, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Meeting to Take Place on July 25, 2025 Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial...
May 02, 2025 11:48 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
May 01, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

GLEN ALLEN, Va., May 01, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
March 04, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
February 25, 2025 09:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval Adial...